The frequency and associated factors of infusion-related reactions to rituximab for patients with rheumatoid arthritis

Basit Öğe Kaydı
dc.contributor.authorPekdiker, Mete
dc.date.accessioned2024-09-19T16:22:08Z
dc.date.available2024-09-19T16:22:08Z
dc.date.issued2023
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjectives: Rituximab is an effective biological agent for treating patients with rheumatoid arthritis (RA). Rheumatologists can avoid rituximab therapy because of infusion-related reactions (IRR). There is a lack of data about rituximab-related IRR, especially in rituximab-naïve patients with RA; therefore, we aimed to determine the frequency and associated factors of rituximab-related IRR in these patients. Methods: Baseline demographic, laboratory, and treatment data were noted. One course of rituximab was used in two infusions to 95 rituximab-naïve patients with RA. Standardized premedication was administered before infusions. Rates, severity, and management of IRR were recorded. Efficacy and infections were also noted if there were. Results: Ninety-four of 95 patients completed the rituximab course successfully. We observed a total of 23 IRRs in 20 patients. The frequency of IRR was 12.1%, and serious IRR was 0.52%. Grade 1-2-3 IRRs had a rate of 52.2%, 30.4%, and 17.4%, respectively; grade 4 or 5 IRR wasn’t detected. Age <60 years, anti-CCP <200U/ml and absence of biologic agent use before rituximab was significantly higher in patients with IRR than without IRR (p=0.01, p=0.002, p=0.01 respectively). We found out that if only the disease age is above 60 months, it is protective against IRR as per the results of multivariate model analysis. Conclusion: Results supported that rituximab is a safe biological agent option for patients with RA at secondary central hospitals. Identified risk factors of IRR need to be corroborated in larger studies for safer rituximab therapy.en_US
dc.identifier.doi10.17944/interdiscip.1351896
dc.identifier.endpage110en_US
dc.identifier.issn2980-1915
dc.identifier.issue49en_US
dc.identifier.startpage105en_US
dc.identifier.trdizinid1199384en_US
dc.identifier.urihttps://doi.org/10.17944/interdiscip.1351896
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1199384
dc.identifier.urihttps://hdl.handle.net/20.500.12483/15628
dc.identifier.volume14en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofInterdisciplinary medical journalen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRituximaben_US
dc.subjectInfusion-Related Reactionsen_US
dc.subjectRheumatoid Arthritisen_US
dc.subjectRisk Factorsen_US
dc.titleThe frequency and associated factors of infusion-related reactions to rituximab for patients with rheumatoid arthritisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
15628.pdf
Boyut:
263.65 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu